PDCD1 and hepatocellular carcinoma: A small retrospective study reported acceptable toxicity and an ORR of 16% for dual ICI treatment (anti-CTLA-4 [cytotoxic T-lymphocyte antigen-4] plus anti-PD1 [programmed cell death 1]) in 25 patients with HCC who progressed on prior ICIs.15